A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Neoplasms
Non-Muscle Invasive Bladder Neoplasms
Carcinoma in Situ

Interventions

BIOLOGICAL: Intismeran autogene
BIOLOGICAL: BCG

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]